Genta (GNTA) Announces Initial Clinical Trial Results for G4544, a Novel Potent Drug for Bone Disease
More News related to GNTA
- Genta (GNTA) Announces Initial Clinical Trial Results for G4544, a Novel Potent Drug for Bone Disease
- Genta (GNTA) Announces Corporate Restructuring, Reduces Workforce by 30%
- Genta Inc (GNTA) Auditor Raises 'Going Concern' Doubt - DJ
- FDA Indicates That Genta's (GNTA) Genasense Approval Will Require Additional Confirmatory Data
- Genta (GNTA) Announces Licensing Agreement
More News related to Corporate News
- S&P Announces Change to US Index: TSRA for FIF
- RealNetworks (RNWK) and MTV Networks (VIA-B) to Split Off Joint Venture Rhapsody
- Watts Water (WTS) Board Approves Restructuring Program; Shutting Down 3 Plants, Cutting 95 Jobs
- Transcept Pharmaceuticals (TSPT) Granted U.S. Patent Covering Intermezzo Formulation
- AAR (AIR) Predicts Impact of Mesa's Bankruptcy on Q3 Results
Genta Incorporated (OTCBB: GNTA) announced the release of final results from the Company's Phase 1 clinical trial of G4544, a proprietary small molecule that is intended as a treatment for diseases associated with accelerated bone loss. Results showed that the drug was very well-tolerated, and that blood levels were achieved in a range that is known to be clinically bioactive. The data were featured in a poster session at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago on Saturday, May 31, 2008.
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
